Triaziquone
Chemical compound
Clinical data | |
---|---|
Other names |
|
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.000.629 |
Chemical and physical data | |
Formula | C12H13N3O2 |
Molar mass | 231.255 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
| |
NY (what is this?) (verify) |
Triaziquone is a drug used in chemotherapy.
It is aziridinylbenzoquinone-based, and may have potential antineoplastic activity. [1]
It is an alkylating agent. It can react with DNA to form intrastrand crosslinks. It is a member of aziridines as well. [2]
References
- ^ PubChem. "Triaziquone". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-10-10.
- ^ Huang CH, Kuo HS, Liu JW, Lin YL (June 2009). "Synthesis and antitumor evaluation of novel bis-triaziquone derivatives". Molecules (Basel, Switzerland). 14 (7): 2306–16. doi:10.3390/molecules14072306. PMC 6255275. PMID 19633605.
- v
- t
- e
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e